Cutia Therapeutics (HK:2487) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cutia Therapeutics has announced that its CFO and Executive Director, Mr. Huang Yuqing, has demonstrated his confidence in the company by purchasing 50,000 additional shares with personal funds. The transaction, with an average price of HK$14.954 per share, suggests a strong belief in the firm’s future. The company reassured that it maintains compliance with public float requirements as per Hong Kong Stock Exchange rules.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.